Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

TRIPS drug amendment a start

Paul Webster
CMAJ February 21, 2017 189 (7) E289; DOI: https://doi.org/10.1503/cmaj.1095391
Paul Webster
Toronto, Ontario
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

In a development termed “extremely important” by World Trade Organization (WTO) Director-General Roberto Azevêdo, many poor- and middle-income countries may at last be able to import cheap generic drugs for high-mortality diseases such as HIV/AIDS, tuberculosis, malaria and pneumonia.

It’s been a long road. An amendment to the WTO’s Trade Related Aspects of Intellectual Property Rights (TRIPS) regime was first proposed in 2003. On Jan. 23, 2017, the required two-thirds of the WTO’s 164 member-countries finally agreed to adopt the amendment which allows drug-deprived countries to request WTO “waivers” so they can import very cheap generic drugs.

Previously under TRIPS, the governments of poor and developing countries could get “compulsory licenses” to produce inexpensive generic medicines for their domestic markets without the patent owners’ consent. But TRIPS blocked them from exporting to other needy nations. This meant that countries without manufacturing capacity couldn’t access cheap generic drugs from nations with compulsory licenses.

“[The amendment] gives legal certainty that generic medicines can be exported at reasonable prices to satisfy the needs of countries with no pharmaceutical production capacity, or those with limited capacity,” Azevêdo said in a videotaped statement.

But some point to failed Canadian legislation as evidence that more than the amendment is required. Canada’s 2004 legislation (The Jean Chrétien Pledge to Africa) followed much the same process as Azevêdo now describes as a breakthrough. But 13 years after Canada’s law was passed, only one shipment of generics from Canada has been exported to a needy nation.

Figure

Drug-deprived countries will be allowed to import cheap generic drugs, but barriers remain.

Image courtesy of MSF Mumbai

An international analyst says the amendment alone will have a “very limited” impact without further action from the WTO. Dr. Rohit Malpany, director of policy and analysis for Médecins Sans Frontières (MSF) in Paris says the WTO needs to simplify the waiver application process, provide legal support to applicant nations, support the development of unpatented low-cost new drugs, and force pharmaceutical companies to become much more transparent about their price-setting decisions.

Canada could also have a role, says Richard Elliott, executive director of the Canadian HIV/AIDs Network in Toronto, who says he’s committed to the idea that Canada could use the WTO’s waiver process to help needy nations. “If we are ever going to get this to work, the Liberal government will have to get behind this again in a very forceful, and far more effective way.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (7)
CMAJ
Vol. 189, Issue 7
21 Feb 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TRIPS drug amendment a start
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
TRIPS drug amendment a start
Paul Webster
CMAJ Feb 2017, 189 (7) E289; DOI: 10.1503/cmaj.1095391

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
TRIPS drug amendment a start
Paul Webster
CMAJ Feb 2017, 189 (7) E289; DOI: 10.1503/cmaj.1095391
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Providing abortions to Americans could land Canadian doctors in legal trouble — without CMPA assistance
  • Troubling rise in suicides linked with common food preservative
  • Weak SARS-CoV-2 vaccine booster campaign resurrects specter of health care hesistancy
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire